Tag: astrazeneca

1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of 9.2. 2. Heterologous Pfizer followed by AstraZeneca vaccination was not found to be non-inferior to homologous, two-dose Pfizer vaccination. Evidence Rating Level: 1 (Excellent) Study Rundown: Heterologous prime-boost vaccination schedules involve administering...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering the...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. 2. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there is the...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The neutralizing titer of the vaccinated individuals was nine times lower against B.1.1.7 than the non-B.1.1.7 (Victoria) strain in vitro. Evidence Rating Level: 1 (Excellent) Study Rundown: As vaccines are distributed worldwide, concern...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems across the globe...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems...
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes With many COVID-19 vaccine being studied and approved for emergency use, one important candidate is the chimpanzee adenovirus-vector (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein.1 The University of Oxford developers of this vaccine have a partnership with AstraZeneca. This Phase 1/2...